GSK completes Novartis vaccines purchase; Galena announces positive PhIIb cancer vax results;

> GlaxoSmithKline ($GSK) completed its acquisition of Novartis' ($NVS) vaccine business. Story

> Galena Biopharma announced positive Phase IIa results of its GALE-301 immunotherapy in preventing the recurrence of ovarian and endometrial cancers. Galena also identified an optimal dose. Statement

> Aduro ($ADRO), through a $32 million purchase of Dutch biotech BioNovion, added an in-house preclinical pipeline of antibodies and checkpoint inhibitors. Report

> Researchers at the University of Rochester Medical Center received $3.1 million from the NIH to look for new ways to develop an HIV vaccine. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.